Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease
Identifieur interne : 003813 ( Main/Exploration ); précédent : 003812; suivant : 003814Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease
Auteurs : Theresa A. Zesiewicz [États-Unis] ; Kelly L. Sullivan [États-Unis] ; John L. Maldonado [États-Unis] ; William O. Tatum [États-Unis] ; Robert A. Hauser [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-09.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Anticonvulsants (therapeutic use), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Dyskinesia, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), Female, Humans, Keppra, Levetiracetam, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Pilot Projects, Piracetam (analogs & derivatives), Piracetam (therapeutic use), Treatment, dyskinesia, levetiracetam, levodopa.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , analogs & derivatives : Piracetam.
- chemical , therapeutic use : Anticonvulsants, Antiparkinson Agents, Levodopa, Piracetam.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- Aged, Female, Humans, Male, Middle Aged, Pilot Projects.
Abstract
We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625 ± 277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% ± 12% vs. 61% ± 17%; P = 0.02). Percent on time with troublesome dyskinesia decreased from 23% ± 10% at baseline to 11% ± 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak‐dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20563
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001933
- to stream Istex, to step Curation: 001933
- to stream Istex, to step Checkpoint: 002220
- to stream PubMed, to step Corpus: 003024
- to stream PubMed, to step Curation: 003024
- to stream PubMed, to step Checkpoint: 003029
- to stream Ncbi, to step Merge: 001288
- to stream Ncbi, to step Curation: 001288
- to stream Ncbi, to step Checkpoint: 001288
- to stream Main, to step Merge: 004E97
- to stream PascalFrancis, to step Corpus: 001D50
- to stream PascalFrancis, to step Curation: 000F71
- to stream PascalFrancis, to step Checkpoint: 001D70
- to stream Main, to step Merge: 005248
- to stream Main, to step Curation: 003813
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease</title><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name></author><author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name></author><author><name sortKey="Maldonado, John L" sort="Maldonado, John L" uniqKey="Maldonado J" first="John L." last="Maldonado">John L. Maldonado</name></author><author><name sortKey="Tatum, William O" sort="Tatum, William O" uniqKey="Tatum W" first="William O." last="Tatum">William O. Tatum</name></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9C448C47012553C0CA49E602AB1F33011679209C</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20563</idno><idno type="url">https://api.istex.fr/document/9C448C47012553C0CA49E602AB1F33011679209C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001933</idno><idno type="wicri:Area/Istex/Curation">001933</idno><idno type="wicri:Area/Istex/Checkpoint">002220</idno><idno type="wicri:doubleKey">0885-3185:2005:Zesiewicz T:open:label:pilot</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15954135</idno><idno type="wicri:Area/PubMed/Corpus">003024</idno><idno type="wicri:Area/PubMed/Curation">003024</idno><idno type="wicri:Area/PubMed/Checkpoint">003029</idno><idno type="wicri:Area/Ncbi/Merge">001288</idno><idno type="wicri:Area/Ncbi/Curation">001288</idno><idno type="wicri:Area/Ncbi/Checkpoint">001288</idno><idno type="wicri:doubleKey">0885-3185:2005:Zesiewicz T:open:label:pilot</idno><idno type="wicri:Area/Main/Merge">004E97</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0492939</idno><idno type="wicri:Area/PascalFrancis/Corpus">001D50</idno><idno type="wicri:Area/PascalFrancis/Curation">000F71</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001D70</idno><idno type="wicri:doubleKey">0885-3185:2005:Zesiewicz T:open:label:pilot</idno><idno type="wicri:Area/Main/Merge">005248</idno><idno type="wicri:Area/Main/Curation">003813</idno><idno type="wicri:Area/Main/Exploration">003813</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease</title><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Maldonado, John L" sort="Maldonado, John L" uniqKey="Maldonado J" first="John L." last="Maldonado">John L. Maldonado</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>College of Public Health, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Tatum, William O" sort="Tatum, William O" uniqKey="Tatum W" first="William O." last="Tatum">William O. Tatum</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-09">2005-09</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1205">1205</biblScope><biblScope unit="page" to="1209">1209</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9C448C47012553C0CA49E602AB1F33011679209C</idno><idno type="DOI">10.1002/mds.20563</idno><idno type="ArticleID">MDS20563</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Anticonvulsants (therapeutic use)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Female</term><term>Humans</term><term>Keppra</term><term>Levetiracetam</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Pilot Projects</term><term>Piracetam (analogs & derivatives)</term><term>Piracetam (therapeutic use)</term><term>Treatment</term><term>dyskinesia</term><term>levetiracetam</term><term>levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Piracetam</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term><term>Antiparkinson Agents</term><term>Levodopa</term><term>Piracetam</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term><term>Lévodopa</term><term>Lévétiracétam</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and were at least moderately disabling were treated with LEV in doses up to 3,000 mg for up to 60 days. The primary outcome measure was the percent of the awake day that patients spent on without dyskinesia or with nontroublesome dyskinesia (good on time). The mean dose of LEV at endpoint was 625 ± 277 mg/day. LEV significantly improved percent of the awake day on without dyskinesia or with nontroublesome dyskinesia at endpoint compared to baseline (43% ± 12% vs. 61% ± 17%; P = 0.02). Percent on time with troublesome dyskinesia decreased from 23% ± 10% at baseline to 11% ± 6% at endpoint, although not significantly. There was no significant increase in off time from baseline to endpoint. There was a 56% dropout rate, mostly due to somnolence. In PD patients who experienced peak‐dose dyskinesia for at least 25% of the awake day, LEV significantly improved on time without dyskinesia or with nontroublesome dyskinesia. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li></region><settlement><li>Tampa</li></settlement><orgName><li>Université de Floride du Sud</li></orgName></list><tree><country name="États-Unis"><region name="Floride"><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name></region><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><name sortKey="Maldonado, John L" sort="Maldonado, John L" uniqKey="Maldonado J" first="John L." last="Maldonado">John L. Maldonado</name><name sortKey="Maldonado, John L" sort="Maldonado, John L" uniqKey="Maldonado J" first="John L." last="Maldonado">John L. Maldonado</name><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><name sortKey="Tatum, William O" sort="Tatum, William O" uniqKey="Tatum W" first="William O." last="Tatum">William O. Tatum</name><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003813 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003813 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9C448C47012553C0CA49E602AB1F33011679209C
|texte= Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |